133 related articles for article (PubMed ID: 29877239)
21. A typical bedside-to-bench investigation of leukemogenic driver MEF2D fusion reveals new targeted therapy in B-cell acute lymphoblastic leukemia.
Zhang H; Meng G
Blood Sci; 2022 Jul; 4(3):161-163. PubMed ID: 36518591
[TBL] [Abstract][Full Text] [Related]
22. Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia.
Tvito A; Rowe JM
Expert Opin Biol Ther; 2017 Dec; 17(12):1557-1564. PubMed ID: 29092647
[TBL] [Abstract][Full Text] [Related]
23. Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia.
Choudhry A; O'Brien SM
Drugs Today (Barc); 2017 Dec; 53(12):653-665. PubMed ID: 29517084
[TBL] [Abstract][Full Text] [Related]
24. [Precision medicine and molecular target drugs in pediatric hematologic malignancies: acute lymphoblastic leukemia].
Takita J
Rinsho Ketsueki; 2020; 61(6):657-664. PubMed ID: 32624540
[TBL] [Abstract][Full Text] [Related]
25. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia.
Feng J; Li Y; Jia Y; Fang Q; Gong X; Dong X; Ru K; Li Q; Zhao X; Liu K; Wang M; Tian Z; Jia Y; Wang Y; Lin D; Wei H; Tang K; Mi Y; Wang J
J Hematol Oncol; 2017 Feb; 10(1):61. PubMed ID: 28245838
[TBL] [Abstract][Full Text] [Related]
26. How should we treat older adults with Ph+ adult ALL and what novel approaches are being investigated?
Wieduwilt MJ
Best Pract Res Clin Haematol; 2017 Sep; 30(3):201-211. PubMed ID: 29050693
[TBL] [Abstract][Full Text] [Related]
27. Clinical updates in adult acute lymphoblastic leukemia.
Al Ustwani O; Gupta N; Bakhribah H; Griffiths E; Wang E; Wetzler M
Crit Rev Oncol Hematol; 2016 Mar; 99():189-99. PubMed ID: 26777876
[TBL] [Abstract][Full Text] [Related]
28. ZNF384-Related Fusion Genes in Acute Lymphoblastic Leukemia.
Zhu L; Bai W; Cheng Q; Fang J
Cancer Control; 2023; 30():10732748231182787. PubMed ID: 37306722
[TBL] [Abstract][Full Text] [Related]
29. Advances in adult acute lymphoblastic leukemia therapy.
Aldoss I; Stein AS
Leuk Lymphoma; 2018 May; 59(5):1033-1050. PubMed ID: 28745565
[TBL] [Abstract][Full Text] [Related]
30. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.
Kantarjian HM; DeAngelo DJ; Advani AS; Stelljes M; Kebriaei P; Cassaday RD; Merchant AA; Fujishima N; Uchida T; Calbacho M; Ejduk AA; O'Brien SM; Jabbour EJ; Zhang H; Sleight BJ; Vandendries ER; Marks DI
Lancet Haematol; 2017 Aug; 4(8):e387-e398. PubMed ID: 28687420
[TBL] [Abstract][Full Text] [Related]
31. Next-generation-sequencing of recurrent childhood high hyperdiploid acute lymphoblastic leukemia reveals mutations typically associated with high risk patients.
Chen C; Bartenhagen C; Gombert M; Okpanyi V; Binder V; Röttgers S; Bradtke J; Teigler-Schlegel A; Harbott J; Ginzel S; Thiele R; Husemann P; Krell PF; Borkhardt A; Dugas M; Hu J; Fischer U
Leuk Res; 2015 Sep; 39(9):990-1001. PubMed ID: 26189108
[TBL] [Abstract][Full Text] [Related]
32. Cloning and functional characterization of MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins created by a variant t(1;19)(q23;p13.3) in acute lymphoblastic leukemia.
Prima V; Gore L; Caires A; Boomer T; Yoshinari M; Imaizumi M; Varella-Garcia M; Hunger SP
Leukemia; 2005 May; 19(5):806-13. PubMed ID: 15744350
[TBL] [Abstract][Full Text] [Related]
33. Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia.
Wei G; Wang J; Huang H; Zhao Y
J Hematol Oncol; 2017 Aug; 10(1):150. PubMed ID: 28821272
[TBL] [Abstract][Full Text] [Related]
34. Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation.
Xiao H; Wang LM; Luo Y; Lai X; Li C; Shi J; Tan Y; Fu S; Wang Y; Zhu N; He J; Zheng W; Yu X; Cai Z; Huang H
Oncotarget; 2016 Jan; 7(3):2696-708. PubMed ID: 26527318
[TBL] [Abstract][Full Text] [Related]
35. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
[TBL] [Abstract][Full Text] [Related]
36. [Adult acute lymphoblastic leukemia: current therapies and future perspectives].
Hayakawa F
Rinsho Ketsueki; 2016 Mar; 57(3):230-7. PubMed ID: 27076233
[TBL] [Abstract][Full Text] [Related]
37. Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.
Paul S; Rausch CR; Kantarjian H; Jabbour EJ
Future Oncol; 2017 Oct; 13(25):2233-2242. PubMed ID: 28776425
[TBL] [Abstract][Full Text] [Related]
38. Acute lymphoblastic leukemia in adolescents and young adults.
Rytting ME; Jabbour EJ; O'Brien SM; Kantarjian HM
Cancer; 2017 Jul; 123(13):2398-2403. PubMed ID: 28328172
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of relapsed or refractory acute lymphoblastic leukemia].
Imai K
Rinsho Ketsueki; 2017; 58(10):1995-2003. PubMed ID: 28978841
[TBL] [Abstract][Full Text] [Related]
40. Current and future management of Ph/BCR-ABL positive ALL.
Maino E; Sancetta R; Viero P; Imbergamo S; Scattolin AM; Vespignani M; Bassan R
Expert Rev Anticancer Ther; 2014 Jun; 14(6):723-40. PubMed ID: 24611626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
